PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerviewpress.com

subscribe
share





Elizabeth A. Raetz, MD / Rachel Rau, MD - Meeting Therapeutic Challenges in Pediatric ALL: Expert Perspectives on the Use of Asparaginase Compounds


Go online to PeerView.com/ZBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert faculty panel focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric acute lymphoblastic leukemia (ALL) therapy by pairing a sample case scenario with a short lecture designed to illustrate the tactics and techniques for addressing hypersensitivity and effectively utilizing available asparaginase options. Upon completion of this accredited CE activity, participants should be better able to: Describe the clinical implications of Escherichia coli asparaginase hypersensitivity and asparaginase discontinuation in pediatric acute lymphoblastic leukemia (ALL), Summarize evidence surrounding the use of Erwinia chrysanthemi asparaginase, including recombinant formulations, as a component of multiagent chemotherapy for pediatric ALL, Develop protocols for the management of E coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.


share







 2021-06-23  1h1m